<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC5706110/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706110/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Gynecologic oncology"><meta name="citation_title" content="Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study"><meta name="citation_authors" content="Kathleen N. Moore, David Tritchler, Kenneth M. Kaufman, Heather Lankes, Michael C.J. Quinn, Linda Van Le, Andrew Berchuck, Floor J. Backes, Krishnansu S. Tewari, Roger B. Lee, Joshua P. Kesterson, Robert M. Wenham, Deborah K. Armstrong, Thomas C. Krivak, Michael A. Bookman, Michael J. Birrer"><meta name="citation_date" content="November 2017"><meta name="citation_issue" content="2"><meta name="citation_volume" content="147"><meta name="citation_firstpage" content="396"><meta name="citation_doi" content="10.1016/j.ygyno.2017.08.024"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC5706110/?report=abstract"><meta name="citation_pmid" content="28935272"><meta name="DC.Title" content="Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Kathleen N. Moore"><meta name="DC.Contributor" content="David Tritchler"><meta name="DC.Contributor" content="Kenneth M. Kaufman"><meta name="DC.Contributor" content="Heather Lankes"><meta name="DC.Contributor" content="Michael C.J. Quinn"><meta name="DC.Contributor" content="Linda Van Le"><meta name="DC.Contributor" content="Andrew Berchuck"><meta name="DC.Contributor" content="Floor J. Backes"><meta name="DC.Contributor" content="Krishnansu S. Tewari"><meta name="DC.Contributor" content="Roger B. Lee"><meta name="DC.Contributor" content="Joshua P. Kesterson"><meta name="DC.Contributor" content="Robert M. Wenham"><meta name="DC.Contributor" content="Deborah K. Armstrong"><meta name="DC.Contributor" content="Thomas C. Krivak"><meta name="DC.Contributor" content="Michael A. Bookman"><meta name="DC.Contributor" content="Michael J. Birrer"><meta name="DC.Date" content="2017 Nov"><meta name="DC.Identifier" content="10.1016/j.ygyno.2017.08.024"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study"><meta property="og:type" content="article"><meta property="og:description" content="This study evaluated single nucleotide polymorphisms (SNPs) associated with progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC.Patients enrolled in GOG-172 and 182 who provided specimens for translational research ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706110/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC5706110/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC5706110/pdf/nihms921497.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8C5436DD5ADBD1000000000225013D.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5706110%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed">PubMed</option><option value="books" class="last">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC5706110</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Gynecol Oncol</a></span>. Author manuscript; available in PMC 2017 Nov 29.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28935272" target="pmc_ext" ref="reftype=publisher&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">Gynecol Oncol. 2017 Nov; 147(2): 396–401. </span></a></div><span class="fm-vol-iss-date">Published online 2017 Sep 19. </span> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1016%2Fj.ygyno.2017.08.024" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1016/j.ygyno.2017.08.024</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC5706110</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS921497</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/28935272">28935272</a></div></div></div></div><h1 class="content-title">Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study<sup><sup><a href="#FN2" rid="FN2" class=" fn">☆</a></sup><sup>,</sup><sup><a href="#FN3" rid="FN3" class=" fn">☆☆</a></sup></sup></h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Moore%20KN%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002893144544" co-class="co-affbox">Kathleen N. Moore</a>,<sup>a,</sup><sup>*</sup> <a href="/pubmed/?term=Tritchler%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002888964736" co-class="co-affbox">David Tritchler</a>,<sup>b</sup> <a href="/pubmed/?term=Kaufman%20KM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002888331584" co-class="co-affbox">Kenneth M. Kaufman</a>,<sup>c,</sup><sup>d</sup> <a href="/pubmed/?term=Lankes%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002883362736" co-class="co-affbox">Heather Lankes</a>,<sup>e</sup> <a href="/pubmed/?term=Quinn%20MC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002894573856" co-class="co-affbox">Michael C.J. Quinn</a>,<sup>f</sup> <a href="/pubmed/?term=Van%20Le%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002892282832" co-class="co-affbox">Linda Van Le</a>,<sup>g</sup> <a href="/pubmed/?term=Berchuck%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002930410752" co-class="co-affbox">Andrew Berchuck</a>,<sup>h</sup> <a href="/pubmed/?term=Backes%20FJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002889012400" co-class="co-affbox">Floor J. Backes</a>,<sup>i</sup> <a href="/pubmed/?term=Tewari%20KS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002888909216" co-class="co-affbox">Krishnansu S. Tewari</a>,<sup>j</sup> <a href="/pubmed/?term=Lee%20RB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002882560640" co-class="co-affbox">Roger B. Lee</a>,<sup>k</sup> <a href="/pubmed/?term=Kesterson%20JP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002893760592" co-class="co-affbox">Joshua P. Kesterson</a>,<sup>l</sup> <a href="/pubmed/?term=Wenham%20RM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002884930000" co-class="co-affbox">Robert M. Wenham</a>,<sup>m</sup> <a href="/pubmed/?term=Armstrong%20DK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002887777232" co-class="co-affbox">Deborah K. Armstrong</a>,<sup>n</sup> <a href="/pubmed/?term=Krivak%20TC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002895681248" co-class="co-affbox">Thomas C. Krivak</a>,<sup>o</sup> <a href="/pubmed/?term=Bookman%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002889422032" co-class="co-affbox">Michael A. Bookman</a>,<sup>p</sup> and  <a href="/pubmed/?term=Birrer%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272" class="affpopup" co-rid="_co_idm140002893530960" co-class="co-affbox">Michael J. Birrer</a><sup>q</sup>, on behalf of the Ovarian Cancer Association Consortium</div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140002893144544"><h3 class="no_margin">Kathleen N. Moore</h3><p>  <sup>a</sup>Stephenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA</p><div>Find articles by <a href="/pubmed/?term=Moore%20KN%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Kathleen N. Moore</a></div></div><div id="_co_idm140002888964736"><h3 class="no_margin">David Tritchler</h3><p>  <sup>b</sup>The Gynecologic Oncology Group Biostatistics Office, Buffalo, NY, USA</p><div>Find articles by <a href="/pubmed/?term=Tritchler%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">David Tritchler</a></div></div><div id="_co_idm140002888331584"><h3 class="no_margin">Kenneth M. Kaufman</h3><p>  <sup>c</sup>Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA</p><p>  <sup>d</sup>US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA</p><div>Find articles by <a href="/pubmed/?term=Kaufman%20KM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Kenneth M. Kaufman</a></div></div><div id="_co_idm140002883362736"><h3 class="no_margin">Heather Lankes</h3><p>  <sup>e</sup>Statistics and Data Management Center, NRG Oncology, Buffalo, NY, USA</p><div>Find articles by <a href="/pubmed/?term=Lankes%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Heather Lankes</a></div></div><div id="_co_idm140002894573856"><h3 class="no_margin">Michael C.J. Quinn</h3><p>  <sup>f</sup>Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia</p><div>Find articles by <a href="/pubmed/?term=Quinn%20MC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Michael C.J. Quinn</a></div></div><div id="_co_idm140002892282832"><h3 class="no_margin">Linda Van Le</h3><p>  <sup>g</sup>UNC, Chapel Hill, Department of OB/GYN, Chapel Hill, NC 27599, USA</p><div>Find articles by <a href="/pubmed/?term=Van%20Le%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Linda Van Le</a></div></div><div id="_co_idm140002930410752"><h3 class="no_margin">Andrew Berchuck</h3><p>  <sup>h</sup>Duke University Medical Center, Room 25172, Durham, NC 27710, USA</p><div>Find articles by <a href="/pubmed/?term=Berchuck%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Andrew Berchuck</a></div></div><div id="_co_idm140002889012400"><h3 class="no_margin">Floor J. Backes</h3><p>  <sup>i</sup>Ohio State University, Wexner Medical Center, Hilliard, OH 43026, USA</p><div>Find articles by <a href="/pubmed/?term=Backes%20FJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Floor J. Backes</a></div></div><div id="_co_idm140002888909216"><h3 class="no_margin">Krishnansu S. Tewari</h3><p>  <sup>j</sup>University of California Medical Center, Irvine, CA 92868, USA</p><div>Find articles by <a href="/pubmed/?term=Tewari%20KS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Krishnansu S. Tewari</a></div></div><div id="_co_idm140002882560640"><h3 class="no_margin">Roger B. Lee</h3><p>  <sup>k</sup>Tacoma General Hospital, Tacoma, WA, USA</p><div>Find articles by <a href="/pubmed/?term=Lee%20RB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Roger B. Lee</a></div></div><div id="_co_idm140002893760592"><h3 class="no_margin">Joshua P. Kesterson</h3><p>  <sup>l</sup>Penn State Medical Center, Hershey, PA, USA</p><div>Find articles by <a href="/pubmed/?term=Kesterson%20JP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Joshua P. Kesterson</a></div></div><div id="_co_idm140002884930000"><h3 class="no_margin">Robert M. Wenham</h3><p>  <sup>m</sup>Moffitt Cancer Center, Tampa, FL, USA</p><div>Find articles by <a href="/pubmed/?term=Wenham%20RM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Robert M. Wenham</a></div></div><div id="_co_idm140002887777232"><h3 class="no_margin">Deborah K. Armstrong</h3><p>  <sup>n</sup>Sidney Kimmel Cancer Center, Division of Medical Oncology, John Hopkins, Baltimore, MD, USA</p><div>Find articles by <a href="/pubmed/?term=Armstrong%20DK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Deborah K. Armstrong</a></div></div><div id="_co_idm140002895681248"><h3 class="no_margin">Thomas C. Krivak</h3><p>  <sup>o</sup>Western Pennsylvania Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Pittsburgh, PA, USA</p><div>Find articles by <a href="/pubmed/?term=Krivak%20TC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Thomas C. Krivak</a></div></div><div id="_co_idm140002889422032"><h3 class="no_margin">Michael A. Bookman</h3><p>  <sup>p</sup>Gynecologic Oncology Research, US Oncology Research Arizona Oncology, Tucson, AZ 85711, USA</p><div>Find articles by <a href="/pubmed/?term=Bookman%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Michael A. Bookman</a></div></div><div id="_co_idm140002893530960"><h3 class="no_margin">Michael J. Birrer</h3><p>  <sup>q</sup>Gynecological Oncology, Massachusetts General Hospital, Department of Medicine, Boston, MA, USA</p><div>Find articles by <a href="/pubmed/?term=Birrer%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28935272">Michael J. Birrer</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140002895154368_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140002895154368_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140002895154368_ai" style="display:none"><div class="fm-affl" id="A1" lang="en">  <sup>a</sup>Stephenson Oklahoma Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA</div><div class="fm-affl" id="A2" lang="en">  <sup>b</sup>The Gynecologic Oncology Group Biostatistics Office, Buffalo, NY, USA</div><div class="fm-affl" id="A3" lang="en">  <sup>c</sup>Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA</div><div class="fm-affl" id="A4" lang="en">  <sup>d</sup>US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA</div><div class="fm-affl" id="A5" lang="en">  <sup>e</sup>Statistics and Data Management Center, NRG Oncology, Buffalo, NY, USA</div><div class="fm-affl" id="A6" lang="en">  <sup>f</sup>Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia</div><div class="fm-affl" id="A7" lang="en">  <sup>g</sup>UNC, Chapel Hill, Department of OB/GYN, Chapel Hill, NC 27599, USA</div><div class="fm-affl" id="A8" lang="en">  <sup>h</sup>Duke University Medical Center, Room 25172, Durham, NC 27710, USA</div><div class="fm-affl" id="A9" lang="en">  <sup>i</sup>Ohio State University, Wexner Medical Center, Hilliard, OH 43026, USA</div><div class="fm-affl" id="A10" lang="en">  <sup>j</sup>University of California Medical Center, Irvine, CA 92868, USA</div><div class="fm-affl" id="A11" lang="en">  <sup>k</sup>Tacoma General Hospital, Tacoma, WA, USA</div><div class="fm-affl" id="A12" lang="en">  <sup>l</sup>Penn State Medical Center, Hershey, PA, USA</div><div class="fm-affl" id="A13" lang="en">  <sup>m</sup>Moffitt Cancer Center, Tampa, FL, USA</div><div class="fm-affl" id="A14" lang="en">  <sup>n</sup>Sidney Kimmel Cancer Center, Division of Medical Oncology, John Hopkins, Baltimore, MD, USA</div><div class="fm-affl" id="A15" lang="en">  <sup>o</sup>Western Pennsylvania Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Pittsburgh, PA, USA</div><div class="fm-affl" id="A16" lang="en">  <sup>p</sup>Gynecologic Oncology Research, US Oncology Research Arizona Oncology, Tucson, AZ 85711, USA</div><div class="fm-affl" id="A17" lang="en">  <sup>q</sup>Gynecological Oncology, Massachusetts General Hospital, Department of Medicine, Boston, MA, USA</div><div id="FN1"><sup>*</sup>Corresponding author at: Stephenson Oklahoma Cancer Center, 800 NE 10th Street, Oklahoma City, OK 73104, USA</div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140002895154368_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28935272" target="pmc_ext" ref="reftype=publisher&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Gynecol Oncol</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC5706110/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="2" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Figure S1.</strong></div><div><a href="/pmc/articles/PMC5706110/bin/NIHMS921497-supplement-Figure_S1.pdf" data-ga-action="click_feat_suppl">NIHMS921497-supplement-Figure_S1.pdf</a><span style="color:gray"> (49K)</span></div><div class="small guid">GUID:&nbsp;BA012287-F468-4259-815B-A043CE7B255A</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Figure S2.</strong></div><div><a href="/pmc/articles/PMC5706110/bin/NIHMS921497-supplement-Figure_S2.pdf" data-ga-action="click_feat_suppl">NIHMS921497-supplement-Figure_S2.pdf</a><span style="color:gray"> (37K)</span></div><div class="small guid">GUID:&nbsp;4C57F55B-7A20-41DE-BDF6-66012B3ADD85</div></div></dd></dl></div><div id="idm140002891129440" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140002891129440title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">Objective</h3><p id="P1" class="p p-first-last">This study evaluated single nucleotide polymorphisms (SNPs) associated with progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC.</p></div><div id="S2" class="sec"><h3 id="S2title">Methods</h3><p id="P2" class="p p-first-last">Patients enrolled in GOG-172 and 182 who provided specimens for translational research and consent were included. Germline DNA was evaluated with the Illumina’s HumanOMNI1-Quad beadchips and scanned using Illumina’s iScan optical imaging system. SNPs with allele frequency &gt; 0.05 and genotyping rate &gt; 0.98 were included. Analysis of SNPs for PFS and OS was done using Cox regression. Statistical significance was determined using Bonferroni corrected <em>p</em>-values with genomic control adjustment.</p></div><div id="S3" class="sec"><h3 id="S3title">Results</h3><p id="P3" class="p p-first-last">The initial GWAS analysis included 1,124,677 markers in 396 patients. To obtain the final data set, quality control checks were performed and limited to serous tumors and self-identified Caucasian race. In total 636,555 SNPs and 289 patients passed all the filters. The pre-specified statistical level of significance was 7.855e<sup>−08</sup>. No SNPs met this criteria for PFS or OS, however, two SNPs were close to significance (rs10899426 <em>p</em>-2.144e<sup>−08</sup>) (rs6256 <em>p</em>-9.774e<sup>−07</sup>) for PFS and 2 different SNPs were identified (rs295315 <em>p</em>-7.536e<sup>−07</sup>; rs17693104 <em>p</em>-7.734e<sup>−07</sup>) which were close to significance for OS.</p></div><div id="S4" class="sec sec-last"><h3 id="S4title">Conclusions</h3><p id="P4" class="p p-first-last">Using the pre-specified level of significance of 1 × 10<sup>−08</sup>, we did not identify any SNPs of statistical significance for OS or PFS, however several were close. The SNP’s identified in this GWAS study will require validation and these preliminary findings may lead to identification of novel pathways and biomarkers.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Genome-wide association, Advanced stage serous ovarian, Primary peritoneal cancer</span></div></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">1. Introduction</h2><p id="P5" class="p p-first">Epithelial ovarian cancer (EOC) is the most lethal gynecologic oncology malignancy. In 2017 there will be approximately 22,440 newly diagnosed cases leading to 14,080 deaths in the United States. The overall high mortality seen in patients with EOC may be in large part due to 70% being diagnosed at an advanced stage [<a href="#R1" rid="R1" class=" bibr popnode">1</a>]. Treatment of patients with advanced stage EOC includes a combination of platinum based chemotherapy and cytoreductive surgery [<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910763">2</a>,<a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910775">3</a>]. A majority of patients will respond to this aggressive approach and achieve complete clinical remission. However, approximately 20% of patients will have platinum resistant disease and progress within six months of primary therapy. Patients who relapse within six months of completing initial treatment are classified as being primary platinum-resistant and have a poor response to secondary treatment with response rates of 7–12% [<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910750">4</a>–<a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910770">6</a>]. These patients are often not just resistant to platinum but resistant to all cytotoxic therapies making them chemotherapy resistant. Historically, patients with primary platinum-resistant disease have an estimated overall survival of 12 months from the time platinum resistance is identified [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910762">7</a>]. Patients who relapse &gt;6 months following primary platinum therapy are termed platinum-sensitive and have better response to secondary platinum-based chemotherapy with response rates of 30–60% depending on the initial platinum free interval. Eventually, those patients with platinum-sensitive disease will develop resistance to platinum therapies and can be classified as acquired platinum-resistant [<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910751">4</a>–<a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910766">6</a>].</p><p id="P6">Mechanisms that underlie resistance to platinum chemotherapy are most likely multi-factorial [<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910761">8</a>,<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910769">9</a>]. Broadly, resistance to anticancer platinum agents can be classified into two categories: first, platinum compounds may not reach intracellular levels needed for response due to inadequate delivery; and second, increased DNA damage repair mechanisms may lead to increased viability of tumor cells, and hence resistance [<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910772">10</a>,<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910767">11</a>]. For example, carboplatin works by binding to DNA and forming DNA adducts leading to intrastrand or interstrand cross-links which disrupt the structure of the DNA molecule, leading to steric changes in the helix. Alteration in the structure of the DNA molecule leads to cellular DNA damage recognition and repair which can result in the continued viability of the cell resulting in platinum-resistance [<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910759">12</a>].</p><p id="P7">Changes in front line schedule and delivery of chemotherapy, better supportive care and increased availability of effective agents for use at the time of recurrence have resulted in modest improvements in overall survival. [<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910777">13</a>] The development of novel targeted agents, germline BRCA screening, and emphasis on personalized therapies is starting to change the landscape for managing patients with ovarian cancer.</p><p id="P8">Factors that determine the aggressiveness of cancer as well as response to chemotherapy may be related to germ line genetic variants other than those related to homologous recombination, which has garnered the most interest and resulted in development of targeted therapies in the form of PARP inhibitors. GWAS studies performed by the international ovarian cancer association consortium (OCAC) have identified 18 common SNPs associated with ovarian cancer risk [<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910768">14</a>]. Five additional common ovarian cancer risk SNPs were identified in a meta-analysis of cancer GWAS studies [<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910765">15</a>]. Studies using GWAS have also been performed to identify common genetic variants that impact progression free and/or overall survival (PFS and OS) of ovarian cancer. An OCAC study by Bolton et al. revealed 2 SNPs at 19p13.11 (rs8170, rs2363956) that were associated with survival in an initial replication, but not in a second phase of replication [<a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910778">16</a>]. Johnatty et al. recently published a large OCAC GWAS of ~2.8 million genotyped and imputed SNPs in 2900 ovarian cancer cases. None of the SNPs reached genome wide significance, but three of the top five loci for survival were associated with long non-coding RNAs [<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910776">17</a>].</p><p id="P9" class="p p-last">This study used GWAS to identify common SNPs associated with PFS and OS among patients diagnosed with advanced stage epithelial ovarian cancer treated on Gynecologic Oncology Group (GOG) protocols 172 and 182. Identification and validation of prognostic and predictive SNPs for PFS and OS could provide candidate SNPs for prospective validation in other GOG phase III trials.</p></div><div id="S6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S6title">2. Patient and methods</h2><p id="P10" class="p p-first">Study population: Patients enrolled on GOG 172 and 182 who had genomic DNA available. DNA was extracted from WBCs recovered from whole blood using the Puregene DNA purification kit (GentraSystems Inc., Minneapolis, MN) or the ABI PRISM 6100 Nucleic Acid Prep Station (Applied Biosystems Inc., Foster City, CA). All studies received approval from their respective human research ethics committees, and all participants provided written informed consent.</p><div id="S7" class="sec"><h3 id="S7title">2.1. GOG 172</h3><p id="P11" class="p p-first-last">Patients enrolled on GOG protocol 172 had stage III EOC with residual disease ≤1 cm following primary cytoreductive surgery (pCRS) and a GOG performance status of 0–2 and normal blood counts. Patients were randomly assigned to receive either 135 mg/m<sup>2</sup> IV paclitaxel over 24 h day 1 followed by 75 mg/m<sup>2</sup> of IV cisplatin day 2 or 135 mg/m<sup>2</sup> of IV paclitaxel over 24 h day 1 followed by 100 mg/m<sup>2</sup> of intraperitoneal (IP) cisplatin day 2 and 60 mg/m<sup>2</sup> of IP paclitaxel day 8. Six total cycles given at 21 days intervals were planned. The primary study endpoints were PFS and OS which were measured from the date of randomization. Full details of the eligibility and results are available in the published manuscript [<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910758">18</a>].</p></div><div id="S8" class="sec"><h3 id="S8title">2.2. GOG 182</h3><p id="P12" class="p p-first-last">Patients enrolled on GOG protocol 182 had stage III or IV EOC with either ≤ or &gt; 1 cm of residual disease following pCRS. They had GOG performance status of 0–2, normal blood counts and no baseline neuropathy greater than grade 1. Patients were randomized into 1 of 5 arms each of which included 8 cycles of triplet or sequential doublet chemotherapy and provided a minimum of 4 cycles of carboplatin and paclitaxel IV. OS and PFS were assessed from the date of randomization. The primary endpoint for this study was overall survival (OS). Details of the treatment arms, modifications, statistical analysis and results are available in the published manuscript. [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910764">19</a>]</p></div><div id="S9" class="sec"><h3 id="S9title">2.3. Single nucleotide polymorphism analysis</h3><p id="P13" class="p p-first-last">Illumina’s Human OMNI1-Quad beadchips (catalog #WG-311-1112) were used. The samples were processed through Illumina’s propriety Infinium HD Super Assay using Illumina’s propriety reagents. 200 ng of genomic DNA was shipped dried down and then re-suspended, DNA was amplified with standard whole genome amplification. Samples were fragmented and purified with an isopropanol precipitation, re-suspended in Illumina’s resuspension buffer, denatured and the fragmented strands were hybridized onto 50-mer oligos attached to the beads on the beadchip overnight. A single-base extension was performed in conjunction with staining in order to determine the base at the position of inquiry. Beadchips were washed and coated with a sealant. The chips were finally scanned individually using Illumina’s iScan optical imaging system.</p></div><div id="S10" class="sec"><h3 id="S10title">2.4. SNP quality control</h3><p id="P14" class="p p-first-last">93 individuals were classified as genetic outliers and removed. The first three calculated principal components were used to identify genetic outliers. This paper defined the genetic outliers as any sample that was plus or minus 5 standard deviations from the mean of the first three principal components. All subjects self- identified as Caucasian. To obtain the final data set, several quality control checks were performed. Filters for SNPs with call rate &gt;98% and minor allele frequency &gt;5%, sample genotyping rate &gt;98% and Hardy Weinberg equilibrium threshold of 1e<sup>−08</sup> were implemented. In total 636,555 markers and 289 patients passed all filters. After quality analysis and application of filters the final analysis included 289 women, all Caucasian with epithelial ovarian cancer evaluating 636, 555 SNP’s.</p></div><div id="S11" class="sec sec-last"><h3 id="S11title">2.5. Statistical analysis</h3><p id="P15" class="p p-first-last">SNP variables are coded as allelic dosage. All <em>p</em>-values reported and displayed in figures are adjusted by the appropriate genomic inflation factor. Survival analyses are based on the proportional hazards regression model, controlling the effect of population stratification by including three principal components in the model. Also included in the survival models were residual disease status (yes/no). The Bonferroni threshold for genome-wide significance is 7.855e<sup>−08</sup>.</p></div></div><div id="S12" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S12title">3. Results</h2><div id="S13" class="sec sec-first"><h3 id="S13title">3.1. Overall survival (OS)</h3><p id="P16" class="p p-first">Demographic and tumor characteristics for the patients whose samples were included in this analysis are reported in <a href="/pmc/articles/PMC5706110/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. The proportional hazards regression model for each SNP included allelic dosage, three principal components representing population substructure and residual disease status. The genomic inflation factor for these analyses was 1.036 and all <em>p</em>-values were correspondingly adjusted.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p8">Demographics table.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140002891352048" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="3" colspan="1" valign="top" align="left"></th><th rowspan="1" colspan="1" valign="top" align="left">Total</th><th rowspan="1" colspan="1" valign="top" align="left">GOG 172</th><th rowspan="1" colspan="1" valign="top" align="left">GOG 182</th></tr><tr><th rowspan="1" colspan="1" valign="bottom" align="left">
<hr></th><th rowspan="1" colspan="1" valign="bottom" align="left">
<hr></th><th rowspan="1" colspan="1" valign="bottom" align="left">
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="top" align="left">(<em>N</em> = 289)</th><th rowspan="1" colspan="1" valign="top" align="left">(<em>N</em> = 147)</th><th rowspan="1" colspan="1" valign="top" align="left">(<em>N</em> = 142)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">Age: median (range)</td><td rowspan="1" colspan="1" valign="top" align="left">57.79 (30,87)</td><td rowspan="1" colspan="1" valign="top" align="left">57.22 (34,83)</td><td rowspan="1" colspan="1" valign="top" align="left">59.13 (30,87)</td></tr><tr><td colspan="4" rowspan="1" valign="top" align="left">Stage of disease</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> III</td><td rowspan="1" colspan="1" valign="top" align="left">268</td><td rowspan="1" colspan="1" valign="top" align="left">147</td><td rowspan="1" colspan="1" valign="top" align="left">121</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> IV</td><td rowspan="1" colspan="1" valign="top" align="left">21</td><td rowspan="1" colspan="1" valign="top" align="left">0</td><td rowspan="1" colspan="1" valign="top" align="left">21</td></tr><tr><td colspan="4" rowspan="1" valign="top" align="left">Size of residual disease</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Microscopic</td><td rowspan="1" colspan="1" valign="top" align="left">92</td><td rowspan="1" colspan="1" valign="top" align="left">56</td><td rowspan="1" colspan="1" valign="top" align="left">36</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Gross</td><td rowspan="1" colspan="1" valign="top" align="left">197</td><td rowspan="1" colspan="1" valign="top" align="left">91</td><td rowspan="1" colspan="1" valign="top" align="left">106</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Not assessed</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left"></td></tr><tr><td colspan="4" rowspan="1" valign="top" align="left">Histologic features</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Serous</td><td rowspan="1" colspan="1" valign="top" align="left">220</td><td rowspan="1" colspan="1" valign="top" align="left">110 (50%)</td><td rowspan="1" colspan="1" valign="top" align="left">110(50%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Endometrioid</td><td rowspan="1" colspan="1" valign="top" align="left">19</td><td rowspan="1" colspan="1" valign="top" align="left">8(42%)</td><td rowspan="1" colspan="1" valign="top" align="left">11(58%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Mixed</td><td rowspan="1" colspan="1" valign="top" align="left">18</td><td rowspan="1" colspan="1" valign="top" align="left">13(72%)</td><td rowspan="1" colspan="1" valign="top" align="left">5(28%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Clear Cell</td><td rowspan="1" colspan="1" valign="top" align="left">17</td><td rowspan="1" colspan="1" valign="top" align="left">10(59%)</td><td rowspan="1" colspan="1" valign="top" align="left">7(41%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> Other</td><td rowspan="1" colspan="1" valign="top" align="left">15</td><td rowspan="1" colspan="1" valign="top" align="left">6(40%)</td><td rowspan="1" colspan="1" valign="top" align="left">9(60%)</td></tr><tr><td colspan="4" rowspan="1" valign="top" align="left">Grade</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 1</td><td rowspan="1" colspan="1" valign="top" align="left">20</td><td rowspan="1" colspan="1" valign="top" align="left">9(45%)</td><td rowspan="1" colspan="1" valign="top" align="left">11(55%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 2</td><td rowspan="1" colspan="1" valign="top" align="left">107</td><td rowspan="1" colspan="1" valign="top" align="left">60(56%)</td><td rowspan="1" colspan="1" valign="top" align="left">47(44%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 3</td><td rowspan="1" colspan="1" valign="top" align="left">157</td><td rowspan="1" colspan="1" valign="top" align="left">76(48%)</td><td rowspan="1" colspan="1" valign="top" align="left">81(52%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> NA</td><td rowspan="1" colspan="1" valign="top" align="left">5</td><td rowspan="1" colspan="1" valign="top" align="left">2(40%)</td><td rowspan="1" colspan="1" valign="top" align="left">3(60%)</td></tr><tr><td colspan="4" rowspan="1" valign="top" align="left">Performance Status</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 0</td><td rowspan="1" colspan="1" valign="top" align="left">133</td><td rowspan="1" colspan="1" valign="top" align="left">64(48%)</td><td rowspan="1" colspan="1" valign="top" align="left">69(52%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 1</td><td rowspan="1" colspan="1" valign="top" align="left">136</td><td rowspan="1" colspan="1" valign="top" align="left">70(51%)</td><td rowspan="1" colspan="1" valign="top" align="left">66(49%)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"> 2</td><td rowspan="1" colspan="1" valign="top" align="left">20</td><td rowspan="1" colspan="1" valign="top" align="left">13(65%)</td><td rowspan="1" colspan="1" valign="top" align="left">7(35%)</td></tr></tbody></table></div><div id="largeobj_idm140002891352048" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5706110/table/T1/?report=objectonly">Open in a separate window</a></div></div><p id="P17">The Manhattan plot for the OS <em>p</em>-values is shown in <a href="/pmc/articles/PMC5706110/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>. The horizontal red line at the top of the plot displays the Bonferroni threshold. None of the tests exceed the cutoff, so none attain genome-wide statistical significance.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC5706110/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140002893691376" class="figure"><a href="/pmc/articles/PMC5706110/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5706110_nihms921497f1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms921497f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5706110/bin/nihms921497f1.jpg"></a></div><div id="largeobj_idm140002893691376" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC5706110/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC5706110/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Fig. 1</a></div><!--caption a7--><div class="caption"><p id="__p6">Manhattan plot for overall survival. The horizontal red line displays the Bonferroni threshold which was not crossed by any polymorphism indicating lack of statistical significance.</p></div></div></div><p id="P18"><a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary Fig. 1 (supplemental figure)</a> is a quantile-quantile plot comparing the OS test statistics to the values expected under the null distribution. The red line represents the equality of observed and expected values. This plot suggests a slight bump at moderate, non-significant levels, which are possibly effects not discoverable due to low power.</p><p id="P19" class="p p-last">Although none are significant, we list the top ten OS SNP effects which are candidates for inclusion in a higher powered study (<a href="/pmc/articles/PMC5706110/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). Ten SNPs were identified for OS; rs295315 (<em>p</em> = 7.536e<sup>−07</sup>) chromosome (Ch) 3, rs17693104 (<em>p</em> = 7.734e<sup>−07</sup>) Ch 10, rs868767 (<em>p</em> = 1.826e<sup>−06</sup>) Ch 3, rs2050203 (<em>p</em> = 3.904e<sup>−06</sup>) Ch20, rs11621975 (<em>p</em> = 5.186e<sup>−06</sup>) Ch 14, rs17548007 (<em>p</em> = 5.288e<sup>−06</sup>) Ch 12, rs202280 (<em>p</em> = 6.246e<sup>−06</sup>) Ch 8, rs1564271 (<em>p</em> = 8.683e<sup>−06</sup>) Ch 10, rs10899426 (<em>p</em> = 9.003e<sup>−06</sup>) Ch 11, rs4618572 (<em>p</em> = 9.182e<sup>−06</sup>) Ch 6. All <em>p</em>-values are adjusted for genomic inflation. SNP rs17693104 is located in the SDH2D4B gene and rs1564271 is located in the PDSS1 gene.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p9">SNPs associated with OS.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140002892598832" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="left">SNP</th><th rowspan="1" colspan="1" valign="middle" align="left">Chromosome</th><th rowspan="1" colspan="1" valign="middle" align="left">Significance</th><th rowspan="1" colspan="1" valign="middle" align="left">HR</th><th rowspan="1" colspan="1" valign="middle" align="left">Associated Gene</th><th rowspan="1" colspan="1" valign="middle" align="left">Discussion</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">rs295315</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 3</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 7.536e<sup>−07</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.82</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs17693104</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 10</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 7.734e<sup>−07</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.65</td><td rowspan="1" colspan="1" valign="top" align="left">SH2D4B</td><td rowspan="1" colspan="1" valign="top" align="left">Associated with capecitabine sensitivity [<a href="#R20" rid="R20" class=" bibr popnode">20</a>]</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs868767</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 3</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 1.826e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">2.12</td><td rowspan="1" colspan="1" valign="top" align="left">LOC646730</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs2050203</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 20</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 3.904e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.78</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs11621975</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 14</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 5.186e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">2.31</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs17548007</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 12</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 5.288e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.86</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs202280</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 8</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 6.246e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.50</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs1564271</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 10</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 8.683e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.62</td><td rowspan="1" colspan="1" valign="top" align="left">PDSS1</td><td rowspan="1" colspan="1" valign="top" align="left">Defects in PDSS1 cause coenzyme Q10 deficiency [<a href="#R21" rid="R21" class=" bibr popnode">21</a>]</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs10899426</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 11</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 9.003e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">2.29</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs4618572</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 6</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 9.182e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.86</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr></tbody></table></div><div id="largeobj_idm140002892598832" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5706110/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><p id="__p10" class="p p-first-last">Ch = chromosome; SH2D4B = SH2 containing domain 4b; PDSS1 = prenyl (decaprenyl) diphosphate synthase, subunit 1 HR = hazard ratio.</p></div></div></div></div><div id="S14" class="sec sec-last"><h3 id="S14title">3.2. Progression-free survival (PFS)</h3><p id="P20" class="p p-first">The proportional hazards regression model for each SNP included allelic dosage, three principal components representing population substructure and residual disease status. The genomic inflation factor for these analyses was 1.102 and all <em>p</em>-values were correspondingly adjusted.</p><p id="P21">The Manhattan plot for the PFS <em>p</em>-values is shown in <a href="/pmc/articles/PMC5706110/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a>. The horizontal red line at the top of the plot displays the Bonferroni threshold. None of the tests exceed the cutoff, so none attain genome-wide statistical significance.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC5706110/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140002888983088" class="figure"><a href="/pmc/articles/PMC5706110/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5706110_nihms921497f2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms921497f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5706110/bin/nihms921497f2.jpg"></a></div><div id="largeobj_idm140002888983088" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC5706110/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC5706110/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Fig. 2</a></div><!--caption a7--><div class="caption"><p id="__p7">Manhattan plot for progression free survival. The horizontal red line displays the Bonferroni threshold which was not crossed by any polymorphism indicating lack of statistical significance.</p></div></div></div><p id="P22"><a href="#SD2" rid="SD2" class=" supplementary-material">Supplementary Fig. 2 (supplemental figure)</a> is a quantile-quantile plot comparing the PFS test statistics to the values expected under the null distribution. The red line represents the equality of observed and expected values. This plot suggests a slight bump at moderate, nonsignificant levels, which are possibly effects not discoverable due to low power.</p><p id="P23" class="p p-last">Although none are significant, we list the top ten PFS SNP effects which are candidates for inclusion in a higher powered study (<a href="/pmc/articles/PMC5706110/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). The ten SNPS with largest estimated effect on PFS are rs10899426 (<em>p</em> = 2.144e<sup>−07</sup>) Ch 11, rs6256 (<em>p</em> = 9.774e<sup>−07</sup>) Ch 11, rs10832063 (<em>p</em> = 4.534e<sup>−06</sup>) Ch 11, (rs10500780 <em>p</em> = 4.634e<sup>−06</sup>) Ch 11, rs281358 (<em>p</em> = 1.137e<sup>−05</sup>) Ch 17, rs17163580 (<em>p</em> = 1.173e<sup>−05</sup>) Ch 1, rs17011846 (<em>p</em> = 1.173e<sup>−05</sup>) Ch 1, rs227147 (<em>p</em> = 1.381e<sup>−05</sup>), rs11782341 (<em>p</em> = 2.049e<sup>−05</sup>), rs7011443 (<em>p</em> = 2.142e<sup>−05.</sup>). All <em>p</em>-values are adjusted for genomic inflation. The genes involved include PTH, BTBD10, DISP1, UTS2, TUSC3, and CSMD1.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p11">SNPs associated with PFS.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140002883157360" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="left">SNP</th><th rowspan="1" colspan="1" valign="middle" align="left">Chromosome</th><th rowspan="1" colspan="1" valign="middle" align="left">Significance</th><th rowspan="1" colspan="1" valign="middle" align="left">HR</th><th rowspan="1" colspan="1" valign="middle" align="left">Associated Gene</th><th rowspan="1" colspan="1" valign="middle" align="left">Discussion</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">rs10899426</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 11</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 2.144e<sup>−07</sup></td><td rowspan="1" colspan="1" valign="top" align="left">2.74</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6256</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 11</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 9.774e<sup>−07</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.93</td><td rowspan="1" colspan="1" valign="top" align="left">PTH exon 3</td><td rowspan="1" colspan="1" valign="top" align="left">Associated with primary hyper-parathyroidism [<a href="#R22" rid="R22" class=" bibr popnode">22</a>]</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs10832063</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 11</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 4.534e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.80</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs10500780</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 11</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 4.634e<sup>−06</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.79</td><td rowspan="1" colspan="1" valign="top" align="left">BTBD10</td><td rowspan="1" colspan="1" valign="top" align="left">Reduced expression of BTBD10 is related to motor neuron death and ALS</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs281358</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 17</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 1.137e<sup>−05</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.67</td><td rowspan="1" colspan="1" valign="top" align="left">None</td><td rowspan="1" colspan="1" valign="top" align="left">No known clinical significance</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs17163580</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 1</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 1.173e<sup>−05</sup></td><td rowspan="1" colspan="1" valign="top" align="left">2.29</td><td rowspan="1" colspan="1" valign="top" align="left">DISP1</td><td rowspan="1" colspan="1" valign="top" align="left">The protein product of DISP1 is required for normal Hedgehog (Hh) signaling [<a href="#R26" rid="R26" class=" bibr popnode">26</a>].</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs17011846</td><td rowspan="1" colspan="1" valign="top" align="left">Ch1</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 1.173e<sup>−05</sup></td><td rowspan="1" colspan="1" valign="top" align="left">2.29</td><td rowspan="1" colspan="1" valign="top" align="left">DISP1</td><td rowspan="1" colspan="1" valign="top" align="left">The protein product of DISP1 is required for normal Hedgehog (Hh) signaling [<a href="#R26" rid="R26" class=" bibr popnode">26</a>].</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs227147</td><td rowspan="1" colspan="1" valign="top" align="left">Ch1</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 1.381e<sup>−05</sup></td><td rowspan="1" colspan="1" valign="top" align="left">0.65</td><td rowspan="1" colspan="1" valign="top" align="left">UTS2</td><td rowspan="1" colspan="1" valign="top" align="left">Urotensin II may be a significant contributor of angiogenesis and certain polymorphisms have been associated with breast cancer [<a href="#R28" rid="R28" class=" bibr popnode">28</a>]</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs11782341</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 8</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 2.049e<sup>−05</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.67</td><td rowspan="1" colspan="1" valign="top" align="left">CSMD1</td><td rowspan="1" colspan="1" valign="top" align="left">Candidate tumor suppressor gene in colon cancer [<a href="#R27" rid="R27" class=" bibr popnode">27</a>]</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7011443</td><td rowspan="1" colspan="1" valign="top" align="left">Ch 8</td><td rowspan="1" colspan="1" valign="top" align="left"><em>p</em> = 2.142e<sup>−05</sup></td><td rowspan="1" colspan="1" valign="top" align="left">1.49</td><td rowspan="1" colspan="1" valign="top" align="left">TUSC3</td><td rowspan="1" colspan="1" valign="top" align="left">Candidate tumor suppressor gene in ovarian cancer xenograph models</td></tr></tbody></table></div><div id="largeobj_idm140002883157360" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5706110/table/T3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN2"><p id="__p12" class="p p-first-last">Ch = chromosome PTH = parathyroid hormone BTBD10 = BTB (POZ) domain containing 10 ALS = amyotrophic lateral sclerosis DISP1 = dispatched homolog 1 (drosophila) UTS2 = urotensin CSMD1 = CUB and Sushi multiple domains 1 TUSC3 = Tumor Suppressor Candidate 3 HR = hazard ratio.</p></div></div></div></div></div><div id="S15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S15title">4. Discussion</h2><p id="P24" class="p p-first">This study combines prospectively collected biospecimens from two randomized phase III front line EOC trials in an effort to evaluate the association of germline SNPs with outcome for advanced EOC. These studies provide a well annotated data set that includes clinical, pathological, treatment, and patient outcome data. Additionally, pathological review was performed by expert gynecologic pathologists to confirm ovarian cancer diagnosis. Patients whose pathology did not pass pathologic review were not included in this analysis. As stated in the methods, to avoid the genetic heterogeneity associated with ethnicity and histology, this analysis was limited to patients with self- reported Caucasian ethnicity. With the combination of excellent genomic and clinical data, this data set allows for GWAS evaluation of genes associated with PFS and OS in patients with advanced stage EOC.</p><p id="P25" class="p">In this GWAS study we did not identify any SNPs that met the Bonferroni threshold for significance for association with either OS or PFS. We did identify 10 candidate SNP’s associated with OS and an additional 10 candidate SNPs associated with PFS in patients with advanced stage serous EOC which may be interesting to reconsider in studies with higher power.</p><div id="S16" class="sec sec-last"><h3 id="S16title">4.1. Overall survival</h3><p id="P26" class="p p-first">Among the 10 SNPs with potential association with overall survival, none have definitive association with cancer related outcomes. Two SNPs were located near genes; rs17693104 is located near the SH2 containing domain 4b (SH2D4b) on chromosome 10 and rs1564271 is located near the prenyl (decaprenyl) diphosphate synthase, subunit 1 (PDSS1). SNPs near SH2D4b, specifically rs6586111 and rs7915642 do have possible correlation with sensitivity to capecitabine across multiple cancer cell lines [<a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910753">20</a>]. rs1564271 is located near PDSS1, defects of which cause Coenzyme Q deficiency which is associated with myalgic encephalomyelitis/chronic fatigue syndrome but has no association thus far with outcomes in malignancies [<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910754">21</a>].</p><p id="P27">Progression Free Survival: SNP rs6256 is located in Ch11 within the PTH gene and does have a functional association with primary hyper-parathyroid syndrome [<a href="#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651980934">22</a>]. SNP rs6256 has been evaluated as a risk factor for colon cancer with the hypothesis being that calcium plays a protective role and activates the tumor suppressor gene E-cadherin in human colonic epithelium. Alteration in calcium homeostasis either through the calcium sensing receptor (CaSR) or through variants in PTH might play a role in colon cancer tumorigenesis. A case control study (350 colon cancer cases and 510 controls) was performed in which rs6256 as well as rs1801725 (a variant of the CaSR gene) were evaluated. There was no difference between the genotype or allelic frequencies between cases and controls [<a href="#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910771">23</a>]. In a meta-analysis of candidate SNPs affecting serum calcium found that rs10500780, a variant of PTH, was not significantly associated with serum calcium levels or associated sequelae such as bone and mineral metabolism and cardiovascular mortality [<a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910779">24</a>]. While it is interesting that two of our most significant SNPs were associated with PTH and calcium homeostasis, the importance to ovarian cancer outcome and risk has not been demonstrated.</p><p id="P28">SNP rs10500780 has no known functional significance itself but is associated with BTBD10 the protein expression of which is related to motor neuron death and amyotrophic lateral sclerosis [<a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910757">25</a>]. SNPs rs17011846 and rs17163580 are associated with the DISP1 gene and have implicated to be involved in the Hedgehog signaling pathway in cancer. Studies in non-small cell lung cancer tumor microarray data demonstrate a negative association between PFS and OS and overexpression of DISP1 [<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910773">26</a>]. This particular SNP has no known clinical association currently.</p><p id="P29">SNP rs11782441 is in the CSMD1 gene which is a candidate tumor suppressor gene. Loss of CSMD1 expression is associated with high tumor grade and poor survival in invasive ductal breast carcinoma [<a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910752">27</a>] and SNP rs227147 is associated with the gene UTS2 (Urotensin II) the function of which is felt to contribute to angiogenesis and certain polymorphisms (not this one) have been associated with breast cancer risk [<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910756">28</a>].</p><p id="P30">Finally, SNP rs7011443 is found within the TUSC3 gene which is another candidate tumor suppressor gene. Epigenetic silencing of this gene has been associated with poor prognosis and is an independent negative prognostic biomarker for PFS and OS in ovarian cancer. The molecular role of TUSC3 in ovarian cancer is not known [<a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910774">29</a>].</p><p id="P31">Recently, the OCAC reported on a genome wide analysis which included patients with EOC from 13 OCAC studies. Patients included in The Cancer Genome Atlas (TCGA) were used as a validation set. Included patients underwent a cytoreductive surgery and were of European ancestry. 2901 patients made up the main data set with a subset of 1098 who were known to have received ≥4 cycles of paclitaxel and carboplatin chemotherapy. This study evaluated over 2.8 million SNPs for association with EOC outcome and identified SNPs at 5 loci with significance for overall and progression free survival. These SNPs included rs6674079, rs7950311 rs4910232, rs2549714, rs3795247. Three of these SNPs (rs6674079, rs4910232 and rs2549714) were found to be located in long coding RNAs. This is significant in that long coding RNAs are transcripts that have been associated with cancer progression through their impact on regulatory functions including epigenetic control, regulation of chromatin structure, regulation of angiogenesis and others [<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910760">17</a>]. We attempted to evaluate these 5 SNPs in our dataset. 3 of the SNPs were available and none were significant for PFS or OS. These included PFS (rs6674079; rs7950311 and rs4910232) and OS (rs6674079; rs7950311 and rs4910232) analysis.</p><p id="P32">In collaboration with the OCAC investigators, the top 10 SNPs identified in the GOG dataset were evaluated in a large dataset with 6160 patients with data on OS and 5596 patients with data on PFS. When the dataset was restricted to those patient who received at least 4 cycles of “standard chemotherapy” this number was 2620 patients. Only Euro-pean samples as determined by principal component analysis were included [<a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651910755">30</a>]. Samples underwent analysis via OncoArray which is a custom designed Illumina array consisting of 533,000 variants. 260,660 of these variants comprise the GWAS analysis for this OCAC study [<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_651980935">31</a>]. The top 10 SNPs for PFS and OS were evaluated in this data set both in all histologies as well as a high grade serous only subset and none were validated for either PFS or OS [<a href="#R32" rid="R32" class=" bibr popnode">32</a>].</p><p id="P33">In this GWAS study we did not identify any SNPs that met the Bonferroni threshold for significance in their association with PFS and OS but we did identified 10 candidate SNP’s for both PFS and OS which might be interesting on further evaluation in higher powered studies. It is interesting in that the SNP rs10899426 was found on both lists as possibly associated with PFS and OS and this is worthy of further evaluation in future studies.</p><p id="P34" class="p p-last"><a href="#SD1" rid="SD1" class=" supplementary-material">Supplementary data</a> to this article can be found online at <a href="http://dx.doi.org/10.1016/j.ygyno.2017.08.024" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://dx.doi.org/10.1016/j.ygyno.2017.08.024</a>.</p></div></div><div id="unreferenced-ft" class="tsec sec headless whole_rhythm"><div class="unreferenced">​
                    <div class="boxed-text-box whole_rhythm hide-overflow" id="BX1"><div class="caption"><h3 id="idm140002884450128title">HIGHLIGHTS</h3></div><ul class="unordered" style="list-style-type:disc" id="L1"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
max-label-size=0
--><li><p id="P35">GWAS may identity single nucleotide polymorphisms (SNPs) associated with survival.</p></li><li><p id="P36">This GWAS study failed to identify SNPs associated with PFS or OS.</p></li><li><p id="P37">Larger GWAS analyses may prove more insightful.</p></li></ul></div></div></div><div id="S18" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S18title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Figure S1</h4><div class="sup-box half_rhythm" id="d36e785"><a href="/pmc/articles/PMC5706110/bin/NIHMS921497-supplement-Figure_S1.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(49K, pdf)</sup></div></div><div class="sec suppmat" id="SD2"><h4>Figure S2</h4><div class="sup-box half_rhythm" id="d36e789"><a href="/pmc/articles/PMC5706110/bin/NIHMS921497-supplement-Figure_S2.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(37K, pdf)</sup></div></div></div><div id="idm140002879466320" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140002879466320title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN2"><sup>☆</sup>This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office(CA 27469) and the GOG Tissue Bank (CA 27469, CA 114793), the GOG Statistical and Data Center (CA 37517) as well as NRG Oncology SDMC grant U10 CA180822 and the NRG Oncology Operations grant U10CA 180868. Additional grant support came from an NCI grant to Roswell Park Cancer Institute (CA 016056-01). This study was also supported by seed grant funding through the American Cancer Institute via the University of Oklahoma.</p><p class="fn sec" id="FN3"><sup>☆☆</sup>The following GOG member institutions participated in this translational research study: University of Alabama at Birmingham, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University, University of Minnesota Medical School, Emory University Clinic, University of Mississippi Medical Center, Colorado Gynecologic Oncology Group, P.C., University of California at Los Angeles, University of Washington, University of Pennsylvania Cancer Center, Milton S. Hershey Medical Center, Georgetown University Hospital, University of Cincinnati, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University Medical Center, Wake Forest University School of Medicine, Albany Medical College, University of California Medical Center at Irvine, Tufts-New England Medical Center, Rush-Presbyterian-St. Luke’s Medical Center, SUNY Downstate Medical Center, University of Kentucky, Community Clinical Oncology Program, The Cleveland Clinic Foundation, Johns Hopkins Oncology Center, SUNY at Stony Brook, Eastern Pennsylvania GYN/ONC Center, PC, Washington University School of Medicine, Cooper Hospital/University Medical Center, Columbus Cancer Council, University of Massachusetts Medical Center, Fox Chase Cancer Center, Medical University of South Carolina, Women’s Cancer Center, University of Oklahoma, University of Virginia, University of Chicago, Tacoma General Hospital, Thomas Jefferson University Hospital, Case Western Reserve University, Tampa Bay Cancer Consortium, North Shore University Hospital, Brookview Research, Inc.</p><p class="fn sec" id="FN4"></p><p id="__p3" class="p p-first"><strong>Conflict of interest statement</strong></p><p id="__p4" class="p p-last">The authors report the following conflicts of interest: K. Moore reports advisory board participation for Astra Zeneca, Clovis, Immunogen, Tesaro, Genentech/Roche, Advaxis, VBL Therapeutics and Janssen. L. van Lee reports clinical trial grants from Astra Zeneca and Morphotek. K Tewari reports speakers bureau participation for Genentech/Roche, Merck, Astra Zeneca, Vermillion, and Clovis. He also reports steering committee participation with Mateon and consultancy with CARIS. R.Wenham reports speakers bureau participation for Genentech/Roche and Janssen as well as steering committee participation for Tesaro. M Bookman reports advisory board participation with Astra Zenca, Tesaro, Endocyte, Pfizer and Clovis. He reports steering committee participation for Genentech/Roche, Mateon and Abbvie and employment with McKesson Specialty Health and USOR. D. Tritchler, K. Kaufman, H. Lankes, M Quinn, A Berchuck, F Backes, R Lee, J Kesterson, D Armstrong, T Krivak and M Birrer have nothing to disclose.</p><p></p></div></div><div id="idm140002888636000" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140002888636000title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Reis LAG.  In: <span class="ref-journal">SEER Cancer Statistics Review, 1975–2001.</span> EM, Kosary CL, et al., editors. 2001.  <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=SEER+Cancer+Statistics+Review,+1975–2001&amp;author=LAG+Reis&amp;publication_year=2001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Winter WE, 3rd, et al.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>(24):3621–3627.</span> [<a href="/pubmed/17704411" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Prognostic+factors+for+stage+III+epithelial+ovarian+cancer:+a+Gynecologic+Oncology+Group+Study&amp;author=WE+Winter&amp;volume=25&amp;issue=24&amp;publication_year=2007&amp;pages=3621-3627&amp;pmid=17704411&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Hamilton CA, et al.  The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. <span><span class="ref-journal">Gynecol Oncol. </span>2011;<span class="ref-vol">122</span>(3):521–526.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3670691/">PMC free article</a>]</span> [<a href="/pubmed/21683993" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol+Oncol&amp;title=The+impact+of+disease+distribution+on+survival+in+patients+with+stage+III+epithelial+ovarian+cancer+cytoreduced+to+microscopic+residual:+a+Gynecologic+Oncology+Group+study&amp;author=CA+Hamilton&amp;volume=122&amp;issue=3&amp;publication_year=2011&amp;pages=521-526&amp;pmid=21683993&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. <span><span class="ref-journal">Oncologist. </span>1999;<span class="ref-vol">4</span>(2):87–94.</span> [<a href="/pubmed/10337378" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=Extending+the+platinum-free+interval+in+recurrent+ovarian+cancer:+the+role+of+topotecan+in+second-line+chemotherapy&amp;author=MA+Bookman&amp;volume=4&amp;issue=2&amp;publication_year=1999&amp;pages=87-94&amp;pmid=10337378&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Markman M, et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. <span><span class="ref-journal">J Clin Oncol. </span>1991;<span class="ref-vol">9</span>(3):389–393.</span> [<a href="/pubmed/1999708" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Second-line+platinum+therapy+in+patients+with+ovarian+cancer+previously+treated+with+cisplatin&amp;author=M+Markman&amp;volume=9&amp;issue=3&amp;publication_year=1991&amp;pages=389-393&amp;pmid=1999708&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Gore ME, et al.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. <span><span class="ref-journal">Gynecol Oncol. </span>1990;<span class="ref-vol">36</span>(2):207–211.</span> [<a href="/pubmed/2404837" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol+Oncol&amp;title=Treatment+of+relapsed+carcinoma+of+the+ovary+with+cisplatin+or+carboplatin+following+initial+treatment+with+these+compounds&amp;author=ME+Gore&amp;volume=36&amp;issue=2&amp;publication_year=1990&amp;pages=207-211&amp;pmid=2404837&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Colombo N, et al.  Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. <span><span class="ref-journal">J Clin Oncol. </span>2012;<span class="ref-vol">30</span>(31):3841–3847.</span> [<a href="/pubmed/22987083" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Randomized,+open-label,+phase+III+study+comparing+patupilone+(EPO906)+with+pegylated+liposomal+doxorubicin+in+platinum-refractory+or+-resistant+patients+with+recurrent+epithelial+ovarian,+primary+fallopian+tube,+or+primary+peritoneal+cancer&amp;author=N+Colombo&amp;volume=30&amp;issue=31&amp;publication_year=2012&amp;pages=3841-3847&amp;pmid=22987083&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. <span><span class="ref-journal">Nat Rev Cancer. </span>2003;<span class="ref-vol">3</span>(7):502–516.</span> [<a href="/pubmed/12835670" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Ovarian+cancer:+strategies+for+overcoming+resistance+to+chemotherapy&amp;author=R+Agarwal&amp;author=SB+Kaye&amp;volume=3&amp;issue=7&amp;publication_year=2003&amp;pages=502-516&amp;pmid=12835670&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? <span><span class="ref-journal">Cell Cycle. </span>2008;<span class="ref-vol">7</span>(10):1353–1359.</span> [<a href="/pubmed/18418074" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Cycle&amp;title=How+do+real+tumors+become+resistant+to+cisplatin?&amp;author=P+Borst&amp;author=S+Rottenberg&amp;author=J+Jonkers&amp;volume=7&amp;issue=10&amp;publication_year=2008&amp;pages=1353-1359&amp;pmid=18418074&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Fojo T, Bates S. Strategies for reversing drug resistance. <span><span class="ref-journal">Oncogene. </span>2003;<span class="ref-vol">22</span>(47):7512–7523.</span> [<a href="/pubmed/14576855" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Strategies+for+reversing+drug+resistance&amp;author=T+Fojo&amp;author=S+Bates&amp;volume=22&amp;issue=47&amp;publication_year=2003&amp;pages=7512-7523&amp;pmid=14576855&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. <span><span class="ref-journal">Crit Rev Oncol Hematol. </span>2007;<span class="ref-vol">63</span>(1):12–31.</span> [<a href="/pubmed/17336087" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Crit+Rev+Oncol+Hematol&amp;title=Mechanisms+of+resistance+to+cisplatin+and+carboplatin&amp;author=DJ+Stewart&amp;volume=63&amp;issue=1&amp;publication_year=2007&amp;pages=12-31&amp;pmid=17336087&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. <span><span class="ref-journal">Cancer Treat Rev. </span>2007;<span class="ref-vol">33</span>(1):9–23.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1855222/">PMC free article</a>]</span> [<a href="/pubmed/17084534" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Treat+Rev&amp;title=Molecular+mechanisms+of+resistance+and+toxicity+associated+with+platinating+agents&amp;author=CA+Rabik&amp;author=ME+Dolan&amp;volume=33&amp;issue=1&amp;publication_year=2007&amp;pages=9-23&amp;pmid=17084534&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Jayson GC, et al.  Ovarian cancer. <span><span class="ref-journal">Lancet. </span>2014;<span class="ref-vol">384</span>(9951):1376–1388.</span> [<a href="/pubmed/24767708" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Ovarian+cancer&amp;author=GC+Jayson&amp;volume=384&amp;issue=9951&amp;publication_year=2014&amp;pages=1376-1388&amp;pmid=24767708&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Kuchenbaecker KB, et al.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <span><span class="ref-journal">Nat Genet. </span>2015;<span class="ref-vol">47</span>(2):164–171.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4445140/">PMC free article</a>]</span> [<a href="/pubmed/25581431" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Identification+of+six+new+susceptibility+loci+for+invasive+epithelial+ovarian+cancer&amp;author=KB+Kuchenbaecker&amp;volume=47&amp;issue=2&amp;publication_year=2015&amp;pages=164-171&amp;pmid=25581431&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Kar SP, et al.  Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. <span><span class="ref-journal">Cancer Discov. </span>2016;<span class="ref-vol">6</span>(9):1052–1067.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5010513/">PMC free article</a>]</span> [<a href="/pubmed/27432226" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Discov&amp;title=Genome-wide+meta-analyses+of+breast,+ovarian,+and+prostate+cancer+association+studies+identify+multiple+new+susceptibility+loci+shared+by+at+least+two+cancer+types&amp;author=SP+Kar&amp;volume=6&amp;issue=9&amp;publication_year=2016&amp;pages=1052-1067&amp;pmid=27432226&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Bolton KL, et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>(10):880–884.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3125495/">PMC free article</a>]</span> [<a href="/pubmed/20852633" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Common+variants+at+19p13+are+associated+with+susceptibility+to+ovarian+cancer&amp;author=KL+Bolton&amp;volume=42&amp;issue=10&amp;publication_year=2010&amp;pages=880-884&amp;pmid=20852633&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Johnatty SE, et al.  Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the ovarian cancer association consortium. <span><span class="ref-journal">Clin Cancer Res. </span>2015;<span class="ref-vol">21</span>(23):5264–5276.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4624261/">PMC free article</a>]</span> [<a href="/pubmed/26152742" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Genome-wide+analysis+identifies+novel+loci+associated+with+ovarian+cancer+outcomes:+findings+from+the+ovarian+cancer+association+consortium&amp;author=SE+Johnatty&amp;volume=21&amp;issue=23&amp;publication_year=2015&amp;pages=5264-5276&amp;pmid=26152742&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Armstrong DK, et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">354</span>(1):34–43.</span> [<a href="/pubmed/16394300" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Intraperitoneal+cisplatin+and+paclitaxel+in+ovarian+cancer&amp;author=DK+Armstrong&amp;volume=354&amp;issue=1&amp;publication_year=2006&amp;pages=34-43&amp;pmid=16394300&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Bookman MA, et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. <span><span class="ref-journal">J Clin Oncol. </span>2009;<span class="ref-vol">27</span>(9):1419–1425.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2668552/">PMC free article</a>]</span> [<a href="/pubmed/19224846" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Evaluation+of+new+platinum-based+treatment+regimens+in+advanced-stage+ovarian+cancer:+a+phase+III+trial+of+the+Gynecologic+Cancer+Intergroup&amp;author=MA+Bookman&amp;volume=27&amp;issue=9&amp;publication_year=2009&amp;pages=1419-1425&amp;pmid=19224846&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">O’Donnell PH, et al.  Identification of novel germline polymorphisms governing capecitabine sensitivity. <span><span class="ref-journal">Cancer. </span>2012;<span class="ref-vol">118</span>(16):4063–4073.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3413892/">PMC free article</a>]</span> [<a href="/pubmed/22864933" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Identification+of+novel+germline+polymorphisms+governing+capecitabine+sensitivity&amp;author=PH+O’Donnell&amp;volume=118&amp;issue=16&amp;publication_year=2012&amp;pages=4063-4073&amp;pmid=22864933&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Maes M, et al.  Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. <span><span class="ref-journal">Neuro Endocrinol Lett. </span>2009;<span class="ref-vol">30</span>(4):470–476.</span> [<a href="/pubmed/20010505" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro+Endocrinol+Lett&amp;title=Coenzyme+Q10+deficiency+in+myalgic+encephalomyelitis/chronic+fatigue+syndrome+(ME/CFS)+is+related+to+fatigue,+autonomic+and+neurocognitive+symptoms+and+is+another+risk+factor+explaining+the+early+mortality+in+ME/CFS+due+to+cardiovascular+disorder&amp;author=M+Maes&amp;volume=30&amp;issue=4&amp;publication_year=2009&amp;pages=470-476&amp;pmid=20010505&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Au AY, et al.  PTH mutation with primary hyperparathyroidism and undetectable intact PTH. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">359</span>(11):1184–1186.</span> [<a href="/pubmed/18784115" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=PTH+mutation+with+primary+hyperparathyroidism+and+undetectable+intact+PTH&amp;author=AY+Au&amp;volume=359&amp;issue=11&amp;publication_year=2008&amp;pages=1184-1186&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Mahmoudi T, et al.  Parathyroid hormone gene rs6256 and calcium sensing receptor gene rs1801725 variants are not associated with susceptibility to colorectal cancer in Iran. <span><span class="ref-journal">Asian Pac J Cancer Prev. </span>2014;<span class="ref-vol">15</span>(15):6035–6039.</span> [<a href="/pubmed/25124570" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Asian+Pac+J+Cancer+Prev&amp;title=Parathyroid+hormone+gene+rs6256+and+calcium+sensing+receptor+gene+rs1801725+variants+are+not+associated+with+susceptibility+to+colorectal+cancer+in+Iran&amp;author=T+Mahmoudi&amp;volume=15&amp;issue=15&amp;publication_year=2014&amp;pages=6035-6039&amp;pmid=25124570&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Kapur K, et al.  Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene. <span><span class="ref-journal">PLoS Genet. </span>2010;<span class="ref-vol">6</span>(7):e1001035.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2908705/">PMC free article</a>]</span> [<a href="/pubmed/20661308" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Genet&amp;title=Genome-wide+meta-analysis+for+serum+calcium+identifies+significantly+associated+SNPs+near+the+calcium-sensing+receptor+(CASR)+gene&amp;author=K+Kapur&amp;volume=6&amp;issue=7&amp;publication_year=2010&amp;pages=e1001035&amp;pmid=20661308&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">Furuta N, et al.  Reduced expression of BTBD10 in anterior horn cells with Golgi fragmentation and pTDP-43-positive inclusions in patients with sporadic amyotrophic lateral sclerosis. <span><span class="ref-journal">Neuropathology. </span>2013;<span class="ref-vol">33</span>(4):397–404.</span> [<a href="/pubmed/23320755" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuropathology&amp;title=Reduced+expression+of+BTBD10+in+anterior+horn+cells+with+Golgi+fragmentation+and+pTDP-43-positive+inclusions+in+patients+with+sporadic+amyotrophic+lateral+sclerosis&amp;author=N+Furuta&amp;volume=33&amp;issue=4&amp;publication_year=2013&amp;pages=397-404&amp;pmid=23320755&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Rodriguez-Blanco J, et al.  The hedgehog processing pathway is required for NSCLC growth and survival. <span><span class="ref-journal">Oncogene. </span>2013;<span class="ref-vol">32</span>(18):2335–2345.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3821972/">PMC free article</a>]</span> [<a href="/pubmed/22733134" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The+hedgehog+processing+pathway+is+required+for+NSCLC+growth+and+survival&amp;author=J+Rodriguez-Blanco&amp;volume=32&amp;issue=18&amp;publication_year=2013&amp;pages=2335-2345&amp;pmid=22733134&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Kamal M, et al.  Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. <span><span class="ref-journal">Breast Cancer Res Treat. </span>2010;<span class="ref-vol">121</span>(3):555–563.</span> [<a href="/pubmed/19669408" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res+Treat&amp;title=Loss+of+CSMD1+expression+is+associated+with+high+tumour+grade+and+poor+survival+in+invasive+ductal+breast+carcinoma&amp;author=M+Kamal&amp;volume=121&amp;issue=3&amp;publication_year=2010&amp;pages=555-563&amp;pmid=19669408&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Yumrutas O, et al.  The role of the UTS2 gene polymorphisms and plasma urotensin-II levels in breast cancer. <span><span class="ref-journal">Tumour Biol. </span>2015;<span class="ref-vol">36</span>(6):4427–4432.</span> [<a href="/pubmed/25604143" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Tumour+Biol&amp;title=The+role+of+the+UTS2+gene+polymorphisms+and+plasma+urotensin-II+levels+in+breast+cancer&amp;author=O+Yumrutas&amp;volume=36&amp;issue=6&amp;publication_year=2015&amp;pages=4427-4432&amp;pmid=25604143&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Kratochvilova K, et al.  Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. <span><span class="ref-journal">Int J Cancer. </span>2015;<span class="ref-vol">137</span>(6):1330–1340.</span> [<a href="/pubmed/25735931" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Tumor+suppressor+candidate+3+(TUSC3)+prevents+the+epithelial-to-mesenchymal+transition+and+inhibits+tumor+growth+by+modulating+the+endoplasmic+reticulum+stress+response+in+ovarian+cancer+cells&amp;author=K+Kratochvilova&amp;volume=137&amp;issue=6&amp;publication_year=2015&amp;pages=1330-1340&amp;pmid=25735931&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Phelan CM, et al.  Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <span><span class="ref-journal">Nat Genet. </span>2017;<span class="ref-vol">49</span>(5):680–691.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5612337/">PMC free article</a>]</span> [<a href="/pubmed/28346442" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Identification+of+12+new+susceptibility+loci+for+different+histotypes+of+epithelial+ovarian+cancer&amp;author=CM+Phelan&amp;volume=49&amp;issue=5&amp;publication_year=2017&amp;pages=680-691&amp;pmid=28346442&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Amos CI, et al.  The OncoArray Consortium: a network for understanding the genetic architecture of common cancers. <span><span class="ref-journal">Cancer Epidemiol Biomark Prev. </span>2017;<span class="ref-vol">26</span>(1):126–135.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5224974/">PMC free article</a>]</span> [<a href="/pubmed/27697780" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Epidemiol+Biomark+Prev&amp;title=The+OncoArray+Consortium:+a+network+for+understanding+the+genetic+architecture+of+common+cancers&amp;author=CI+Amos&amp;volume=26&amp;issue=1&amp;publication_year=2017&amp;pages=126-135&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5706110&amp;issue-id=302199&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span>Analysis and sample information courtesy of the Ovarian Cancer Association Consortium (OCAC).</span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140002891129440title">Abstract</a></li><li><a href="#S5title">1. Introduction</a></li><li><a href="#S6title">2. Patient and methods</a></li><li><a href="#S12title">3. Results</a></li><li><a href="#S15title">4. Discussion</a></li><li><a href="#S18title">Supplementary Material</a></li><li><a href="#idm140002879466320title">Footnotes</a></li><li><a href="#idm140002888636000title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC5706110/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC5706110/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC5706110/pdf/nihms921497.pdf">PDF (578K)</a></li> | <li><a href="#" data-citationid="PMC5706110" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5706110%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5706110%2F&amp;text=Genome-wide%20association%20study%20evaluating%20single-nucleotide%20polymorphisms%20and%20outcomes%20in%20patients%20with%20advanced%20stage%20serous%20ovarian%20or%20primary%20peritoneal%20cancer%3A%20An%20NRG%20Oncology%2FGynecologic%20Oncology%20Group%20study" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5706110%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="28935272" data-aiid="5706110" data-aid="5706110" data-iid="302199" data-domainid="319" data-domain="nihpa" data-accid="PMC5706110" data-md5="266081eb1550d252a3c0de8c89c2a8f3"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T16:34:39-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal105&amp;ncbi_phid=CE8C5436DD5ADBD1000000000225013D&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5706110%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC5706110/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>